Brent Masel is a Neurology physician. OpenAlex indexes 93 publications with 4,514 citations (h-index 30); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
301 University Blvd
Galveston, TX 775555302
Telephone
409-772-2222Provider last certified this registry record 2 May 2022.
Clinical trials
- Traumatic Brain Injury and the Gut Microbiome
Sponsor: Centre for Neuro Skills
- Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)
Sponsor: The University of Texas Medical Branch, Galveston
- Association of Amino Acid Prevalence and Chronic Brain Injury
Sponsor: Brent Masel
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Cholinesterase Inhibitor34%Donepezil Hcl100%Part D≥28 patientsN-methyl-D-aspartate Receptor Antagonist31.7%Memantine Hcl100%Part D≥28 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The altered TBI fecal microbiome is stable and functionally distinct
Frontiers in Molecular Neuroscience
2024 - Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis
Best Practice & Research Clinical Endocrinology & Metabolism
2023 - Low growth hormone secretion associated with post-acute sequelae SARS-CoV-2 infection (PASC) neurologic symptoms: A case-control pilot study
Molecular and Cellular Endocrinology
2023 - A consensus on optimization of care in patients with growth hormone deficiency and mild traumatic brain injury
Growth Hormone & IGF Research
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”